Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has completed a $41 Million Series B financing. All existing investors — Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures — participated in this round, which was led by a new, undisclosed investor.
“We are pleased to welcome our newest investor and to have the continued support from our current investors for this round of financing,” stated Lawrence M. Blatt, PhD, President and Chief Executive Officer of Alios BioPharma. “This funding will allow Alios to retain ownership and control of our novel, first-in-class anti-respiratory virus development programs.”
{iframe}http://www.marketwatch.com/story/alios-biopharma-raises-41-million-in-series-b-financing-2014-04-07?reflink=MW_news_stmp{/iframe}